P. Sanderson

发表

Azaindoles: moderately basic P1 groups for enhancing the selectivity of thrombin inhibitors.

W. M. Sanders, Youwei Yan, S. D. Lewis, 2003, Bioorganic & medicinal chemistry letters.

Activity of TER286 against human tumor colony-forming units.

D. V. Von Hoff, E. Izbicka, R. Lawrence, 1997, Anti-cancer drugs.

Synergistic drug combination effectively blocks Ebola virus infection

P. Shinn, Wei Zheng, X. Qiu, 2017, Antiviral research.

Efficacious, orally bioavailable thrombin inhibitors based on 3-aminopyridinone or 3-aminopyrazinone acetamide peptidomimetic templates.

J. Vacca, J. Shafer, Z. Chen, 1998, Journal of medicinal chemistry.

Glutathione based approaches to improving cancer treatment.

L. Kauvar, W. D. Henner, P. Sanderson, 1998, Chemico-biological interactions.

Tumor efficacy and bone marrow-sparing properties of TER286, a cytotoxin activated by glutathione S-transferase.

L. Kauvar, D. V. Von Hoff, K. Tew, 1998, Cancer research.

An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo

Q. She, N. Rosen, K. Leander, 2010, Cancer biology & therapy.

Suite of TMPRSS2 Assays for Screening Drug Repurposing Candidates as Potential Treatments of COVID-19

Catherine Z. Chen, P. Shinn, M. Hall, 2022, ACS infectious diseases.

Antithrombotic efficacy of thrombin inhibitor L-374,087: intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosis.

J. Vacca, J. Shafer, S. Gardell, 1999, The Journal of pharmacology and experimental therapeutics.

Preclinical Pharmacokinetics and In Vitro Properties of GS-441524, a Potential Oral Drug Candidate for COVID-19 Treatment

Catherine Z. Chen, A. Wang, E. Padilha, 2022, bioRxiv.

Application of in vitro Drug Metabolism Studies in Chemical Structure Optimization for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)

A. Mutlib, J. McKew, P. Yu, 2019, Front. Pharmacol..

Small, noncovalent serine protease inhibitors

P. Sanderson, 1999, Medicinal research reviews.

Enantioselective complexation of the alanine dipeptide by a C2 host molecule

W. C. Still, P. Sanderson, Ruiping Liu, 1990 .

Enantioselective complexation of simple amides by a C2 host molecule

W. C. Still, J. Kilburn, P. Sanderson, 1989 .

Potent, orally bioavailable somatostatin agonists: good absorption achieved by urea backbone cyclization.

A. Patchett, J. Schaeffer, R. Mosley, 1999, Bioorganic & medicinal chemistry letters.

Efficient Synthesis of 1,9-Substituted Benzo[h][1,6]naphthyridin-2(1H)-ones and Evaluation of their Plasmodium falciparum Gametocytocidal Activities.

R. M. Fisher, K. Williamson, A. Simeonov, 2017, ACS combinatorial science.

In vitro evaluation of imidazo[4,5-c]quinolin-2-ones as gametocytocidal antimalarial agents.

K. Williamson, A. Simeonov, Wei Zheng, 2016, Bioorganic & medicinal chemistry letters.

The phenyldimethylsilyl group as a masked hydroxy group

I. Fleming, P. Sanderson, R. Henning, 1995 .

L-374,087, an efficacious, orally bioavailable, pyridinone acetamide thrombin inhibitor.

J. Vacca, J. Shafer, Z. Chen, 1998, Bioorganic & medicinal chemistry letters.

Small, low nanomolar, noncovalent thrombin inhibitors lacking a group to fill the 'distal binding pocket'.

Youwei Yan, L. Kuo, S. D. Lewis, 2003, Bioorganic & medicinal chemistry letters.

C6 modification of the pyridinone core of thrombin inhibitor L-374,087 as a means of enhancing its oral absorption.

J. Vacca, S. Gardell, S. D. Lewis, 1998, Bioorganic & medicinal chemistry letters.

Chapter 8. Anticoagulants: Inhibitors of thrombin and factor Xa

P. Sanderson, 2001 .

Small, Low Nanomolar, Noncovalent Thrombin Inhibitors Lacking a Group to Fill the “Distal Binding Pocket”.

Youwei Yan, L. Kuo, S. D. Lewis, 2003 .

3-amino-4-sulfonylpyridinone acetamide and related pyridothiadiazine thrombin inhibitors.

Youwei Yan, S. D. Lewis, E. A. Lyle, 2003, Bioorganic & medicinal chemistry letters.

Small, noncovalent serine protease inhibitors

P E Sanderson, P. Sanderson, 1999, Medicinal research reviews.

L-373,890, An achiral, noncovalent, subnanomolar thrombin inhibitor

J. Vacca, S. Gardell, A. Mulichak, 1997 .

Thrombin inhibitor design.

A. Naylor-Olsen, A M Naylor-Olsen, P E Sanderson, 1998, Current medicinal chemistry.

Metabolism-directed optimization of 3-aminopyrazinone acetamide thrombin inhibitors. Development of an orally bioavailable series containing P1 and P3 pyridines.

Daniel R McMasters, James C Barrow, W. M. Sanders, 2003, Journal of medicinal chemistry.

Rapid antimicrobial susceptibility test for identification of new therapeutics and drug combinations against multidrug-resistant bacteria

Noel Southall, P. Shinn, Wei Zheng, 2016, Emerging microbes & infections.

L‐373,890, an Achiral, Noncovalent, Subnanomolar Thrombin Inhibitor.

J. Vacca, S. Gardell, A. Mulichak, 1997 .

3-amino-4-sulfonylpyridinone acetamide and related pyridothiadiazine thrombin inhibitors.

Youwei Yan, S. D. Lewis, E. A. Lyle, 2003, Bioorganic & medicinal chemistry letters.

Discovery of 3-substituted aminocyclopentanes as potent and orally bioavailable NR2B subtype-selective NMDA antagonists.

A. Dilella, T. Mcdonald, D. Reiss, 2011, ACS chemical neuroscience.

A one-pot conversion of the phenyldimethylsilyl group into a hydroxyl group

I. Fleming, P. Sanderson, 1987 .

The synthesis of thrombin inhibitor L-370,518 via an α-hydroxy-β-lactam

P. Sanderson, K. J. Cutrona, 1996 .

Novel indole-3-sulfonamides as potent HIV non-nucleoside reverse transcriptase inhibitors (NNRTIs).

G. McGaughey, Youwei Yan, L. Gabryelski, 2008, Bioorganic & medicinal chemistry letters.

Discovery of potent, selective 4-fluoroproline-based thrombin inhibitors with improved metabolic stability.

Youwei Yan, J. Vacca, B. Wong, 2006, Bioorganic & medicinal chemistry.

A Suite of TMPRSS2 Assays for Screening Drug Repurposing Candidates as Potential Treatments of COVID-19

Catherine Z. Chen, P. Shinn, M. Hall, 2022, bioRxiv.

Drug combination therapy increases successful drug repositioning.

Wei Zheng, Wei Sun, Wei Zheng, 2016, Drug discovery today.

Characterization of the Two-step Pathway for Inhibition of Thrombin by α-Ketoamide Transition State Analogs*

R. Freidinger, S. Brady, J. Shafer, 1998, The Journal of Biological Chemistry.

Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva

Wei Zheng, E. Place, A. Bullock, 2020, bioRxiv.

Torin 2 Derivative, NCATS-SM3710, Has Potent Multistage Antimalarial Activity through Inhibition of P. falciparum Phosphatidylinositol 4-Kinase (Pf PI4KIIIβ).

M. Wilkerson, K. Williamson, D. Caridha, 2020, ACS pharmacology & translational science.

Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs

Paul Shinn, Wei Zheng, Jennifer Kouznetsova, 2014, Emerging Microbes & Infections.

Novel anticoagulants based on direct inhibition of thrombin and factor Xa.

S. Gardell, P. Sanderson, 1998, Coronary artery disease.

The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents

Lynn A. Hyde, J. Uslaner, Sean M. Smith, 2011, Neuropharmacology.

An Enzymatic TMPRSS2 Assay for Assessment of Clinical Candidates and Discovery of Inhibitors as Potential Treatment of COVID-19

M. Hall, A. Simeonov, M. Shen, 2020, ACS pharmacology & translational science.

An Enzymatic TMPRSS2 Assay for Assessment of Clinical Candidates and Discovery of Inhibitors as Potential Treatment of COVID-19

M. Hall, A. Simeonov, M. Shen, 2020, bioRxiv.

Abstract #3714: In vitro and in vivo antitumor activities of MK-2206, a new allosteric Akt inhibitor

P. Majumder, K. Leander, H. Hatch, 2009 .

Drug combination therapy increases successful drug repositioning.

Wei Zheng, Wei Sun, P. Sanderson, 2016, Drug discovery today.